Introduction
Prostate cancer is currently the second leading cause of male death from malignant diseases in the developed countries (Landis et al., 1999) . The molecular mechanisms underlying carcinogenesis and malignant dissemination of prostatic cancer may involve a series of complicated molecular events (Foster et al., 1999 . To understand these complicated events, identification of the genes involved in the malignant progression of cancer cells is essential. Using recently developed differential display (Liang and Pardee, 1992)-derived techniques (Ke et al., 1999a, b; Jing et al., 2000b) , we have identified a number of genes expressed differentially between benign and malignant model cell lines. Through a 'subtractive selection' from this large number of candidate genes, at least two candidates have been characterized as important genes whose increased or diminished expression may have important effects on the malignant progression of the model cancer cells (Jing et al., 2000a (Jing et al., , 2002 . One such gene is that coding for cutaneous fatty acid-binding protein (C-FABP).
C-FABP was originally isolated from psoriatic skin samples. It is a small (15 kDa) cytoplasmic protein and is typical of the FABP family of proteins in that it binds long-chain fatty acids with high affinity (Madsen et al., 1992) . C-FABP and its fatty acid-binding activity have been detected in endothelial cells of the microvasculature of such organs as placenta, heart, skeletal muscle, small intestine, lung and renal medulla, as well as in Clara and goblet cells of the colon (Bass, 1988; Masouye et al., 1997) . In addition to breast tissues, increased levels of C-FABP have also been detected in malignant tumours of the bladder and pancreas (Celis et al., 1996; Østergaard et al., 1997; Sinha et al., 1999) , indicating that C-FABP may also play a role in malignant progression in these tissues. Although the precise role of C-FABP in these tissues is not clear, it is likely to be involved in binding and transporting intracellular fatty acids, some of which are signalling molecules reported to be involved in carcinogenesis (Glatz and Vander Vusse, 1997; Xu et al., 1999) .
In our previous work, C-FABP was one of the candidate genes, which exhibited the most pronounced differences in their expression levels between benign and malignant breast and prostate epithelial cell lines (Jing et al., 2000a, b) . Transfection of a C-FABP-expression construct into a benign, nonmetastatic rat mammary (Rama) 37 epithelial cell which line which has been established for assaying the metastatic capability of isolated genes (Chen et al., 1997; Ke et al., 1998) , has generated a pool of transfectants expressing high level of C-FABP. Inoculation of the C-FABP-expression transfectants into syngeneic Wistar-Furth rats produced a significant number of animals with metastases, whereas the control transfectants generated by the vector alone yielded no such metastases (Jing et al., 2000a, b) . These results have demonstrated that the elevated expression of C-FABP can induce the malignant dissemination of the rat mammary model cells. Thus, C-FABP is a metastasis-inducing gene in that system, capable of promoting malignant dissemination of primary tumour cells under suitable conditions. Tumorigenesis and metastasis are two related, but distinctive processes in cancer development. Although C-FABP has been shown to promote metastasis in the Rama 37 cells, it is not clear whether this gene is also involved in promoting tumorigenicity. To investigate the biological relevance of our previous findings to prostatic cancer, and particularly to study the possible role of C-FABP in carcinogenesis of prostatic cancer, we have now used the immunocytochemical staining to detect C-FABP expression at the protein level in a large number of normal, benign and malignant prostatic tissues, so as to assess whether the levels of C-FABP are increased significantly in malignant prostatic carcinomas. To study the biological significance of elevated C-FABP, we have used the antisense DNA transfection method to suppress C-FABP expression in a highly malignant prostatic cancer cell line and subsequently tested the invasiveness and tumorigenicity of the resultant transfectants both in vitro and in vivo to study whether suppressing C-FABP expression can inhibit tumorigenicity of the DNA recipient cells. Since the angiogenic factor, vascular endothelial growth factor (VEGF) mediates, at least in part, the metastasis-inducing effect of C-FABP in the rat mammary cells (Jing et al., 2001) , we have also investigated whether the possible inhibitory effect of the suppressed expression of C-FABP on tumorigenicity is also mediated, in part, by suppressing expression of VEGF.
Results

Expression of C-FABP in human prostatic tissues
Immunocytochemistry was performed to detect the expression of C-FABP in normal, benign and malignant prostatic tissues. Among the 76 cases examined, all seven (100%) normal tissues were unstained (Figure 1a ). For the 35 BPH specimens, 25 (71.4%) were unstained (Figure 1b) , 10 (28.6%) were stained positively. For the 34 prostatic carcinomas, the C-FABP expression was increased remarkably: 25 (73.5%) samples were stained positively (Figure 1c, d) , and only nine (26.5%) were unstained. All the positively stained BPH samples were weakly stained, whereas among the 25 positively stained carcinoma samples, 13 (38.2%) were weakly, five (14.7%) were moderately and seven (20.6%) were strongly stained. Among the 34 malignant carcinoma samples, the level of immunoreactive C-FABP was similar between samples with Gleason grades 1-3 and those with Gleason grades 4 and 5. In all, 11 (73.3%) out of 15 samples with Gleason grades 1-3 stained positively, compared to 14 (73.7%) out of 19 samples with Gleason grades 4 and 5. For the 11 positively stained carcinomas with Gleason grades 1-3, five (33.3%) stained weakly, three (20%) stained moderately and another three (20%) stained strongly. Very similar staining intensities were observed in the 14 positively stained carcinomas with Gleason grades 4 and 5: eight (42.1%) stained weakly, two (10.5%) stained moderately and four (21.1%) stained strongly (Table 1) . Positive stains occurred only in the epithelial cells. In some samples, the malignant carcinoma cells stained positively, but the adjacent BPH areas remained unstained (Figure 1e ), while the majority of the stains occurred in the cytoplasm, some nuclear staining was also observed (Figure 1f ).
Generation of antisense transfectants and effect on level of C-FABP
To suppress the expression of C-FABP in PC-3M cells, a plasmid construct (Materials and methods) expressing a reverse C-FABP transcript was transfected into the highly malignant prostatic cancer cells PC-3M, which express a high level of endogenous C-FABP prior to transfection. The C-FABP expressed in the untransfected PC-3M cells, the control transfectants PC-3M-PSV, the antisense DNA transfectant pool (PC-3M-CFABP-P) and the five individual cloned cell lines (PC-3M-CFABP-1 to -5) derived from PC-3M-CFABP-P were assessed by Western blotting (Figure 2a) . The relative level of C-FABP in the control transfectants PC-3M-PSV, compared to that in the parental PC-3M cells, was not significantly changed (Student's t-test, P>0.05) (Figure 2b ). In contrast, the levels of C-FABP in the antisense transfectants pool (PC-3M-CFABP-P) and all its five individual cell-cloned derivatives (PC-3M-CFABP-1 to -5) were significantly reduced (Student's t-test, Po0.05) to 41.2, 26.30, 71.0, 14.5, 23 .0 and 55.1%, respectively, of the level in control PC-3M-PSV cells (Figure 2b) . Thus, transfection with antisense DNA produced a maximum reduction of 6.9-fold and a moderate reduction of 3.8-fold in the level of C-FABP for PC-3M-CFABP-3 and PC-3M-CFABP-1 transfectants, respectively. Both of them were used for further study.
Detection of transfected DNA in the transfectants
To confirm that the reduction in level of C-FABP was the result of antisense DNA transfection, Southern hybridizations were performed to detect both the Neomycin-resistance gene of the pSVneo plasmid and the reverse C-FABP DNA in the HindIII-digested genomic DNA of the recipient cells. While the neo gene was not present in the untransfected, parental PC-3M cells, it was detected in control transfectants, transfectant pool and the two cloned transfectant cell lines (Figure 3a) . When DNA from the same cell lines was hybridized to the C-FABP cDNA probe, several bands were detected in all the five cell lines examined, but when compared to the intensities of these bands in the parental PC-3M cells and in the control vector alonetransfectants PC-3M-PSV, the intensities of these bands were 1.5 times stronger in the transfectant pool PC-3M-CFABP-P, two times stronger in the cloned transfectant line PC-3M-CFABP-1 and three times stronger in PC-3M-CFABP-3.
Cellular properties of transfectants in vitro
The control transfectants PC-3M-PSV and the cloned transfectants PC-3M-CFABP-1 and PC-3M-CFABP-3 were subjected to different assessments in vitro to analyse the effect of reduced C-FABP expression on the properties associated with malignant cells. No morphological difference was observed among the cells from different cell lines. To measure the proliferation rate of cells, the same number of cells from each cell line was cultured in a separate Petri dish. The number of cells in each dish was counted each day for 8 days. No significant difference was found in the growth rates of the three cell lines (results not shown). The invasiveness of the cell lines was measured by migration through an artificial extracellular matrix (ECM) in a Boyden chamber for a fixed period of time (Figure 4 ). For the control transfectants PC-3M-PSV, 1473.8% of the cells invaded the ECM. However, the percentages of the invaded cells from the cell line PC-3M-CFABP-1 and PC-3M-CFABP-3 were significantly reduced from that of the control to 770.6 and 771.2%, respectively (Student's t-test, Po0.05).
Tumorigenicity of the transfectants in vivo
To investigate whether the suppressed expression of C-FABP can reduce tumorigenicity, the control cells PC-3M-PSV and two cloned antisense transfectant cell lines PC-3M-CFABP-1 and PC-3M-CFABP-3 were injected s.c. into the left shoulder region of three groups of 8-week-old, male ICRF immunoincompetent nude mice. The tumour incidence occurred in each group was shown in Table 2 . Tumours started to appear in the animals 3 days after inoculation. The median latent period of group 1 mice (inoculated with PC-3M-PSV cells) was 3.5 days; of group 2 mice (inoculated with PC-3M-CFABP-1 cells) and group 3 mice (inoculated with PC-3M-CFABP-3 cells) were 5 and 6 days, respectively ( Table 2 ). All the animals in groups 1 and 2 developed tumours, while only 75% of the group 3 mice developed tumours, a reduction of 25%. The average volumes of group 2 and group 3 mouse tumours measured every week following inoculation were always considerably less than that of the control group 1 mice ( Figure 5 ). At autopsy 6 weeks after inoculation, the average volume of the tumours produced by group 2 (524789 mm 3 ) and group 3 (3567101 mm 3 ) mice was significantly reduced (Student's t-test, Po0.01) by 2.9-and 4.2-fold, respectively, in comparison with that in the group 1 mice (14957295 mm 3 ).
Level of VEGF in the transfectants
To investigate whether downregulating VEGF expression is a possible mechanism for the decreased tumorigenicity induced by suppressing C-FABP expression, Northern hybridizations were performed to measure the levels of VEGF mRNA in the transfectants. VEGF mRNA was detected both in control cell line PC-3M-PSV and in the three antisense transfectant cell lines (Figure 6a ). Quantitative analysis by scanning the intensities of the bands relative to a control constitutive actin mRNA showed that the level of VEGF in the transfectants, which express lower levels of C-FABP, was a significantly 2.5-fold lower than that measured in the control transfectant PC-3M-PSV (Figure 6b ) (Student's t-test, Po0.05). If the level of VEGF in PC-3M-PSV cells was set at 1, its levels in PC-3M-CFABP-1 and PC-3M-CFABP-3 were 0.4170.03 and 0.4070.04, respectively.
Detection of C-FABP, VEGF and Factor VIII-related antigen in mouse tumours
Immunocytochemical staining was undertaken to detect three proteins (Figure 7 (Figure 7 , c). Strong staining for C-FABP and VEGF was observed in samples removed from group 1 animals (control PC-3M-PSV cells), whereas only moderate to weak staining was observed in tumours removed from group 2 (PC3M-CFABP-1 cells) and group 3 mice (PC3M-CFABP-3 cells). The Factor VIII-related antigen-stained cells were used to assess microvessel density. The average vessel density per high-powered field (hpf) in tumours produced by the control PC-3M-PSV cells was 11.070.7, compared to 4.770.5 and 3.770.4 per hpf in tumours produced by PC-3M-CFABP-1 and PC-3M-CFABP-3 cells, respectively (Table 2) . When the vessel density in tumours produced by the control cells was set at 1, the relative vessel density in tumours produced by PC-3M-CFABP-1 and PC-3M-CFABP-3 Figure 4 Invasive potential in vitro of transfectant cell lines. The invasiveness of a cell line is measured by an in vitro motility assay through ECM and the mean percentage (7s.e.) of cells invaded was obtained from three separate experiments. The invasiveness of the two transfectant-cloned cell lines was significantly reduced (Student's t-test, Po0.05) in comparison with that of the control transfectants PC-3M-PSV Tumour incidence is the percentage of mice with tumours/total number of inoculated animals. b Microvessel is defined as the presence of three or more contiguous Factor VIII-related antigen positive cells. Vessel numbers were recorded from 50 hpf ( Â 5) of 2.5 Â 1.75 mm. For each section, 10 randomly selected fields were counted. The average number of vessels per hpf (mean7s.e.) was calculated from all animals with tumours in each group.
c Average number of vessels per hpf in PC-3M-PSV tumours was set at 1 and the vessel densities of tumours of other groups were calculated relative to that of the PC-3M-PSV tumours. (Table 2 ).
Discussion
The increased activity of oncogenes is an important mechanism for the development and expansion of cancer. However, other genes would appear to be requested for malignant dissemination or metastasis at least in animal model systems in this regard. C-FABP has been recently identified and characterized as metastasis-promoting gene (Jing et al., 2000a) . Its overexpression was previously associated with cancers of urinary bladder and pancreas (Celis et al., 1996; Østergaard et al., 1997; Sinha et al., 1999) . In this work, we have used the immunocytochemistry to show that the number of positively stained malignant carcinoma samples was significantly increased over that of positively stained BPH samples. Moreover, not only more malignant carcinoma samples were stained positively, but also the intensity of staining in the positive carcinoma tissues was much more stronger than that observed in the positive BPH tissues. Thus the results obtained by immunocytochemical staining showed that although the level of C-FABP was not detectable in the normal prostatic tissues, it was increased in BPH samples and further greatly increased in the malignant carcinoma samples. Therefore, the level of C-FABP was associated with malignant progression in prostate cancer, and hence C-FABP may play an important role in its development. However, the levels of staining for C-FABP between the carcinomas with low Gleason grades (grades 1-3) and those with high Gleason grades (grades 4 and 5) were not greatly different: no further increment in C-FABP expression in high-grade carcinomas was detected. These results suggest that although the increased expression of C-FABP may play an important role in the development of prostatic cancer, there is no simple relation between the level of C-FABP and the degree of malignancy. To further investigate the biological significance of the elevated level of C-FABP in carcinomas of the prostate, C-FABP expression in the highly malignant prostatic cancer cells PC-3M was suppressed by cotransfection of a vector expressing a reverse C-FABP transcript to induce the RNase H cleavage activity (Wagner, 1994) to destroy the C-FABP mRNA. Cotransfection of the reverse C-FABP cDNA together with the pSVneo plasmid was necessary because there was no neomycinresistance gene in the reverse transcript-expressing construct (Materials and methods). Although the amount of antisense construct (18 mg) was nine times that of the pSVneo plasmid DNA (2 mg), there was still a possibility that some clones growing in the geneticin medium may harbour only the plasmid DNA. In this work, we ring-cloned and established five individual cellcloned transfectant cell lines to ensure that some would harbour reverse c-FABP DNA as well as pSVneo DNA. Although C-FABP expression was reduced in all of the five clones analysed (Figure 2b ), which demonstrated that the antisense method was effective, the levels of C-FABP between the least effectively suppressed clone, PC-3M-CFABP-2 (71.0% of the control), and the most effectively suppressed clone, PC-3M-CFABP-3 (14.5% of the control), differed by 4.9-fold.
On Southern hybridizations, the intensities of the bands in the antisense transfectant cell pool and its two derivative cell lines were much higher than those detected in the parental PC-3M cells and the control PC-3M-PSV cells (Figure 3b ), indicating that in addition to the normal single copy of the C-FABP gene per haploid cell, the antisense C-FABP DNA was also successfully integrated into the genome of the PC-3M cells. These results together with the fact that the level of C-FABP in the parental PC-3M cells was very similar to that in the control transfectants (PC-3M-PSV), generated by transfection of plasmid DNA alone (Figure 2b) , confirmed that the reduction of the levels of C-FABP in the transfectants was the result of the expression of the reverse transcript, rather than the transfection process. Moreover, when compared to the control transfectants PC-3M-PSV, the intensity of the Southern hybridization bands in the transfectant pool PC-3M-CFABP-P, the transfectant cloned cell lines PC-3M-CFABP-1 and PC-3M-CFABP-3 was, respectively, 1.5-, 2.0-, and 2.5-fold stronger, whereas the level of C-FABP was suppressed by 2.5-, 3.9-, and 6.9-fold, respectively (Figure 2b) . Thus, the more the reverse C-FABP DNA that was integrated the more efficient the C-FABP suppression that was achieved in the recipient cells.
When tested in an in vitro invasion assay, the results that 14% of cells from the control PC-3M-PSV and 7% from the reverse C-FABP transfected PC-3M-CFABP-1 and PC-3M-CFABP-3 cell lines invaded the ECM were (Figure 2b) , a further 3.1-fold reduction from that of PC-3M-CFABP-1, no further reduction of the invasiveness was observed. In contrast, a graded response to the reduction of the levels of C-FABP was observed in the assay for tumorigenesis in vivo. Thus, mice injected with PC-3M-CFABP-1 cells, which expressed 3.8-fold lower level of C-FABP than the control PC-3M-PSV cells, exhibited 100% of tumour incidence, but with a slightly delayed average latent period of 5 (3-7) days and a significant (Student's t-test, Po0.01) reduction of tumour volume (from 14957295 mm 3 in the control) to 524789 mm 3 at autopsy. Mice inoculated with the PC-3M-CFABP-3 cells, which expressed a 6.9-fold lower level of C-FABP than in the control PC-3M-PSV cells, yielded a 25% reduction in tumour incidence, an average latent period of 6 (3-9) days, and a further reduction in tumour volume to 3567101 mm 3 at autopsy, which was significantly different from that of the PC-3M-CFABP-1 cells (Student's t-test, Po0.05). The idea that the reduction of tumour volume in group 2 and group 3 mice was caused by the suppression of C-FABP was further supported by immunocytochemical analysis, which showed that the level of immunoreactive C-FABP in the group 2 tumours (PC-3M-CFABP-1) was reduced compared to that in the group 1 tumours (PC-3M-PSV), and further reduced in the group 3 tumours (PC-3M-CFABP-3) (Figure 7 a1, a2, a3) .
Previously in the rat Rama 37 model (Jing et al., 2000a) , we demonstrated that although increased expression of C-FABP was essential for metastasis of the primary tumour cells, there was no difference in the rate of metastasis produced by transfectants expressing high, but different levels of C-FABP. Therefore, it was suggested that there might be a threshold level of C-FABP, above which, further increase would have no more effect on metastasis. In this work, a threshold effect was observed in the in vitro assay for invasion, but not in the assay for tumorigenicity in vivo. It may be possible that there are different saturating threshold levels of C-FABP for different assays, in which case the in vitro assay for invasion may be more directly related to the ability to generate metastasis in vivo than to generate the initial tumour, that is, tumorigenicity.
Previous work in the rat Rama 37 cell model suggested that C-FABP might induce metastasis of the primary rat tumour cells by upregulating the expression of the VEGF gene (Jing et al., 2001) . VEGF is a potent factor for angiogenesis, which is essential for development and expansion of solid tumours (Veikkola et al., 2001) . In our previous work, we found that the angiogenically active VEGF was produced in high levels (Chen et al., 2000) in the highly malignant prostatic cancer cells Du-145 (Stone et al., 1978) and PC-3 (Kozlowski et al., 1984) (the parental cells of PC3M), both of which also express high levels of C-FABP (Jing et al., 2000a) . It was recently reported that VEGF not only facilitated the malignant progression of cancer cells by angiogenesis, but also stimulated tumorigenicity and metastasis by acting as an autocrine growth factor (Masood et al., 2001) in prostate cancer (Soker et al., 2001; Jackson et al., 2002) . In the present work, we found that suppressing the C-FABP expression by 3.8-and 6.9-fold in PC-3M-CFABP-1 and PC-3M-CFABP-3 cells was associated with a 2.5-fold reduction in the level of VEGF expression in both cases (Figure 6a, b) . A similar association was also observed in the tumours developed from these transfectants (Figure 7b1, b2, b3) . Moreover, microvessel densities in the tumours developed from PC-3M-CFABP-1 and PC-3M-CFABP-3 were decreased by 2.3-and 2.9-fold, respectively, in comparison with that developed from the control PC-3M-PSV cells ( Table 2 ). The results obtained in this work combined with those reported previously (Chen et al., 2000; Jing et al., 2000a Jing et al., , 2001 Masood et al., 2001; Soker et al., 2001; Jackson et al., 2002) suggest that C-FABP acts by upregulating VEGF to induce invasion in vitro and metastasis in vivo, but that additional interactions produced by higher levels of C-FABP are also requested to sustain the integrity of the blood vessel and the primary tumour.
In this work, we demonstrated that C-FABP expression was increased in prostatic carcinoma tissues. We also showed that suppression of tumorigenicity of prostate cancer cells was achievable by reducing the level of C-FABP expression. Thus, C-FABP may be an important gene whose elevated expression may be an important cause for the malignant progression of prostate cancer. Human C-FABP was originally identified as being overexpressed in the psoriatic skin and was thought to play a role in the storage and transport of fatty acids (Madsen et al., 1992) . The expression of the FABP family of proteins, such as liver (L)-FABP, intestine (I)-FABP, heart (H)-FABP, is known to be upregulated by their own ligands, long-chain fatty acids (Storch and Bass, 1990; Masouye et al., 1997; Celis et al., 1999) . Since fatty acids have recently been identified as signalling molecules (Glatz and VanderVusse, 1997), which can be recognized by nuclear peroxisome proliferator-activated receptors (PPARs), such as PPARg (Xu et al., 1999) , the elevated expression of FABP may give rise to an increased total uptake of fatty acids, and hence an enhanced fatty acid signalling activity. Some C-FABP molecules were found by immunocytochemistry to be present in the nucleus of prostatic carcinoma cells (Figure 1f) . This was not a simple artefact since preincubation of the specific antigen abolished the staining. Thus, it may be possible that excessive levels of free fatty acids, as in the colon (Lefebvre et al., 1998; Saez et al., 1998) , may be transported by C-FABP into the nucleus to activate some as yet unknown mechanism, perhaps via PPARg and therefore contribute to carcinogenesis. One such mechanism may be the upregulation of the VEGF gene, since it was suggested recently that VEGF production could be increased by PPARg (Yamakawa et al., 2000) .
Materials and methods
Immunocytochemical detection of C-FABP and other proteins in prostatic tissues
The human prostatic tissues were an archival set held within the surgical pathology archive in the Department of Pathology, University of Liverpool, UK. This study was approved by the Liverpool University Ethics Committee in accordance with the Medical Research Council guidelines. Histological sections (4 mm) of formalin-fixed and paraffin-embedded tissues were cut and processed, as described previously (Deshmukh et al., 1997) . The tissue sections were examined independently by two qualified pathologists and classified as normal, benign prostatic hyperplasia (BPH) and carcinomas. The carcinomas were classified according to their Gleason grades (Gleason et al., 1972) . Immunocytochemistry was used to detect C-FABP in human prostatic tissues, and C-FABP, VEGF and the von Willebrand factor (Factor VIII-related antigen) (for assessing the microvessel density) in tumors produced by the transfectant cells in nude mice. For detection of C-FABP and VEGF, sections were first incubated with the primary anti-C-FABP (Iwaki Glass Corp., Niigata, Japan) and anti-VEGF (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA) sera at a dilution of 1 : 500, and then incubated in a horseradishperoxidase-conjugated polymer (Dako Ltd, Ely, UK). To detect Factor VIII-related antigen, the sections were first incubated with rabbit anti-Factor VIII-related antigen serum (Dako Ltd, Ely, UK) at a dilution of 1 : 1000, and then with donkey anti-rabbit IgG conjugated with biotin (Amersham International, Amersham, UK). The stains of C-FABP and VEGF were visualized with an antibody complex/horseradish peroxidase (Dako Ltd, Ely, UK) staining procedure. The Factor VIII-related antigen staining was visualized with an avidin-biotin complex (Dako Ltd, Ely, UK) staining procedure. Control sections incubated with preimmune serum and with antiserum preincubated with preparations of antigens yielded no specific staining. The sections were counterstained in Mayer's hemalum. The staining of C-FABP in each human sample was graded negative (unstained), weakly positive (+), moderately positive (++) and strongly positive (+++), where a grade of moderately positive (++) is similar in stain intensity to that of normal human epidermis (Watanabe et al., 1997) .
Cell lines and culture conditions
The cell line used throughout this work was the highly metastatic human prostatic cancer cell line PC-3M (Kozlowski et al., 1984) , which was selectively established from the most malignant subpopulations of the human prostatic cancer cell line PC-3 (Kaighn et al., 1978) . The control transfectant PC-3M-PSV in this work was generated by transfection of PC-3M cells with pSV-Neo plasmid DNA (Glaxo Wellcome, London, UK) alone. The PC-3M-CFABP-P cells were a pool of transfectants generated by cotransfecting PC-3M with pSVNeo plasmid and a vector construct expressing an antisense C-FABP transcript. The cell lines PC-3M-CFABP-1 to -5 were established from five individual clones isolated from PC-3M-CFABP-P. PC-3M and transfectants were maintained as monolayer cultures in RPMI 1640 (Life Technologies, Paisley, Scotland) supplemented with 10% (v/v) PCS (Labtech International), hydrocortisone and testosterone (50 ng/ml) (Sigma, Gillingham, UK), penicillin (100 U/ml) and streptomycin (100 mg/ml) (Life Technologies). In addition, the transfectant culture was supplemented with geneticin (Life Technologies) at 1.0 mg/ml.
Construction of the antisense C-FABP DNA vector
A 436 bp cDNA fragment of the protein-coding region of C-FABP was obtained by RT-PCR, using the single-stranded cDNA template achieved by reverse-transcription of mRNA isolated from PC-3 cells. The nucleotide sequence of the primer for the positive strand was 5 0 -ACCATGGCCACAGTTCAG-CA; and the primer sequence for the negative strand was 5 0 -CCTGTCCAAAGTGATGATGGAA. The reaction consisted of 40 cycles of 941C for 30 s, 551C for 1 min and 721C for 30 s. At the end of the last cycle, the reaction was incubated at 721C for 5 min. After the C-FABP sequence was confirmed by automated nucleotide sequencing, the RT-PCR product was inserted into the pGEM-Teasy (Promega, CA, USA) plasmid through the A-T cloning method according to the manufacturer's instructions. The C-FABP fragment was then excised from the construct and cloned into pBluescript (Invitrogen Ltd, Paisley, UK) vector through the EcoRI restriction site to form two new constructs containing the C-FABP fragment inserted in two opposite orientations. The fragment with the reverse orientation, which was confirmed by an automated sequencing, was then excised from the pBluescript vector through the HindIII and XbaI restriction sites and inserted into the pSV-Neo expression vector (Glaxo Wellcome) predigested with HindIII and XbaI. Thus, C-FABP fragment was cloned into the pSV-Neo vector in a reverse orientation to form an antisense construct pSV-CFABPr by replacing a 3075 bp fragment containing the neomycin-resistance gene in the original plasmid. The orientation of C-FABP in the new construct was confirmed by automated nucleotide sequencing through the junctions.
Transfection of the reverse C-FABP-expressing construct
For DNA transfection experiments, exponentially growing PC-3M cells were seeded at a density of 0.5-0.75 Â 10 6 /dish in two (10 cm in diameter) Petri dishes. One dish was transfected with 20 mg of pSV-Neo DNA to generate the control transfectants, using the calcium phosphate method, as that described previously (Chen et al., 1997; Ke et al., 1998) . Another dish was cotransfected with 18 mg of pSV-CFABPr and 2 mg of pSV-Neo DNA to generate a transfectant pool and individual transfectant clones. The resultant cells were passaged at a 1 : 10 dilution in RPMI containing geneticin at 1 mg/ml; the medium was replaced every 3-4 days. When the colonies of transfectants in the dishes grew to about 3 mm in diameter, ring-cloning was used to isolate five stably transfected single-cell clones (PC-3M-CFABP-1 to -5). The remainder of the colonies were pooled to generate the transfectant pool PC-3M-CFABP-P.
Assays for invasiveness and tumorigenicity of the transfectants
The invasiveness of the cells was tested through an invasion assay to test their ability to invade the ECM (Albini et al., 1987; Smith et al., 1998) . Cells (2.5 Â 10 4 ) from each cell line were seeded onto Matrigel-coated membranes with 0.8 mm diameter pores (Sigma, Dorset, UK), and incubated at 371C for 48 h on a Boyden chamber. The invasiveness of each cell line was measured by the percentage of the cells penetrating the membrane. To test tumorigenicity, the cells were injected at 5 Â 10 6 cells/0.2 ml PBS into at a single s.c. site in the left shoulder of 8-week-old male ICRF immunoincompetent nude mice (Harlan Ltd, Newcastle, UK) (eight animals per group). The growth of the tumours in each group was monitored weekly by measuring the length (L), width (W) and height (H) and the tumour volume calculated using the formula: L Â W Â H Â 0.5236 (Janik et al., 1975) . All mice were culled 6 weeks after injection and the resultant rumours were removed and weighed. The tumour tissues were then processed, embedded in paraffin wax and 4 mm histological sections were cut and some stained with Gill's haematoxylin and eosin, others were prepared for immunocytochemical staining. All animal experiments were conducted under UKCCCR guidelines with Home Office Project Licence PPL 40/2270 to Dr Y Ke.
Detection of DNA, RNA and protein in transfectant cells
Southern blot hybridizations were performed for the detection of the neomycin-resistance gene and the reverse C-FABP DNA according to standard procedures, similar to that described previously (Ke et al., 1993) . The C-FABP cDNA probe (452 bp) was prepared by digestion of the pSV-CFABPr plasmid with HindIII and XbaI, and the neomycin-resistance gene probe was an 881 bp DNA fragment obtained by digestion of the pSV-Neo plasmid with BssHII and HindIII. The VEGF probe was a VEGF121 fragment prepared by RT-PCR, using mRNA (100 ng) isolated from PC-3M cells as template, as described previously (Chen et al., 2000) . The sequence of positive strand primer is 5 0 -TCGGGCCTCCGAAACCATGC-3 0 , and for the negative strand primer is 5 0 -CCTGGTGAGAGATCTGGTTC-3 0 . The probes (25 ng each) were radioactively labelled with [a-32 P]dCTP to a specific activity of 0.6-6 Â 10 9 d.p.m./mg DNA by random-primed labelling method (Boehringer Mannheim Biochemica, Mannheim, Germany). Genomic DNA from the control and transfectant cells was extracted using a Genomic tip 500/G kit (Qiagen Inc., Crawley, UK) according to the manufacturer's instructions. The DNA was fragmented with HindIII and separated by electrophoresis on a 0.8% (w/v) agarose gel. The separated DNA fragments were transferred onto a Hybond-N nylon membrane (Amersham Pharmacia, Amersham, UK) and incubated with radioactively labelled probes in a hybridization oven (Techne HB-10; Philip Harris, Manchester, UK) at the predetermined hybridization conditions for 16 h. The radioactive images of the bound probes were visualized by autoradiography following exposure to Kodak XAR-5 film with an intensifying screen. C-FABP mRNA in different transfectant cells was detected by Northern hybridizations. The total cellular RNA was isolated with an RNA midi-kit (QIAGEN GmbH and QIAGEN Inc., Hilden, Germany), and its integrity was verified by the presence of an undegraded band following Northern hybridization to a radioactively labelled actin cDNA probe. Total RNA samples (20 mg each) prepared from the cell lines were electrophoresed under denaturing conditions with formaldehyde in a 0.8% (w/v) agarose gel. After washing the gel, the separated RNAs were transferred onto nylon membranes (Hybond, Amersham, UK) and crosslinked by a brief exposure to a 302 nm UV light. The membranes were incubated at 421C for 4 h in a prehybridization buffer and then hybridized with the radioactively labelled VEGF cDNA probe for 16 h at 421C under conditions similar to those described previously . Radioactivity of the hybridized bands was detected by autoradiography against Kodak XAR-5 films.
The total cellular protein was isolated as whole-cell lysates from the cell lines by lysis in hot (>901C) 2 Â SDS lysis buffer (20 mm Tris-HCl, pH 7.4; 2% (w/v) SDS). Western blot analysis was employed to detect C-FABP in different cell lines, using the ECL system, as described previously . Protein lysates prepared from each cell line were separated by SDS-PAGE under reducing conditions, and transferred to nitrocellulose membrane (Hybond-ECL, Amersham Pharmacia, UK). The membrane was initially incubated in rabbit anti-human C-FABP (Iwaki Glass Corp.) at a 1 : 200 dilution followed by horseradish peroxidase-conjugated swine anti-rabbit IgG (Dako) diluted 1 in 1000, and visualized by standard ECL methods followed by exposure to Kodak XAR-5 film. The relative levels of C-FABP protein were determined by scanning densitometry using Alphalmager 2000 software (Alpha Innotech, Cannock, UK). Antibodies against the constitutively expressed actin protein were also used to standardize the amount of protein loaded for each sample.
